Cargando…

Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials

Lung cancer is the most fatal malignancy worldwide, in part, due to high resistance to cytotoxic therapy. There is need for effective chemo-radio-sensitizers in lung cancer. In recent years, we began to understand the modulation of metabolism in cancer and its importance in tumor progression and sur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Troncone, Michael, Cargnelli, Stephanie M., Villani, Linda A., Isfahanian, Naghmeh, Broadfield, Lindsay A., Zychla, Laura, Wright, Jim, Pond, Gregory, Steinberg, Gregory R., Tsakiridis, Theodoros
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593680/ https://www.ncbi.nlm.nih.gov/pubmed/28915708 http://dx.doi.org/10.18632/oncotarget.17496

Ejemplares similares

Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Need for Early Treatment in Prostate Cancer Patients Managed with Active Surveillance
por: Ahmadi, Elham, et al.
Publicado: (2023)

The impact of staging FDG-PET/CT on treatment for stage III NSCLC - an analysis of population-based data from Ontario, Canada
por: Beers, Craig A., et al.
Publicado: (2023)

Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses
por: Tsakiridis, Evangelia E., et al.
Publicado: (2021)

The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration
por: Villani, Linda A., et al.
Publicado: (2016)

Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK
por: Storozhuk, Y, et al.
Publicado: (2013)

Contemporary real-world radiotherapy outcomes of unresected locally advanced non-small cell lung cancer
por: Gouran-Savadkoohi, Mohammad, et al.
Publicado: (2023)

Chronic modulation of AMP-Kinase, Akt and mTOR pathways by ionizing radiation in human lung cancer xenografts
por: Storozhuk, Yaryna, et al.
Publicado: (2012)

Metformin-induced reductions in tumor growth involves modulation of the gut microbiome()
por: Broadfield, Lindsay A., et al.
Publicado: (2022)

Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α
por: Biziotis, Olga‐Demetra, et al.
Publicado: (2023)

Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC
por: Ballas, Marc S, et al.
Publicado: (2011)

Metformin Sensitizes Leukemia Cells to Vincristine via Activation of AMP-activated Protein Kinase
por: Yi, Yong, et al.
Publicado: (2017)

Metformin Protects Cardiomyocyte from Doxorubicin Induced Cytotoxicity through an AMP-Activated Protein Kinase Dependent Signaling Pathway: An In Vitro Study
por: Kobashigawa, Laura C., et al.
Publicado: (2014)

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
por: Groenendijk, Floris H, et al.
Publicado: (2015)

NLK functions to maintain proliferation and stemness of NSCLC and is a target of metformin
por: Suwei, Dong, et al.
Publicado: (2015)

Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism
por: Liu, Yong, et al.
Publicado: (2017)

Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence
por: Salvatore, Teresa, et al.
Publicado: (2021)

Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner
por: Rattan, R, et al.
Publicado: (2011)

Erratum to: NLK functions to maintain proliferation and stemness of NSCLC and is a target of metformin
por: Suwei, Dong, et al.
Publicado: (2016)

(18)F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer
por: Mesci, Aruz, et al.
Publicado: (2023)

Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies
por: Russo, Alessandro, et al.
Publicado: (2020)

Metabolic Switch and Cytotoxic Effect of Metformin on Burkitt Lymphoma
por: Bagaloni, Irene, et al.
Publicado: (2021)

Current Researches, Rationale, Plausibility, and Evidence Gaps on Metformin for the Management of Hypertensive Disorders of Pregnancy
por: Zhang, Yang, et al.
Publicado: (2020)

Metformin Augments Panobinostat's Anti-Bladder Cancer Activity by Activating AMP-Activated Protein Kinase()()
por: Okubo, Kazuki, et al.
Publicado: (2019)

Ability of metformin to deplete NAD+ contributes to cancer cell susceptibility to metformin cytotoxicity and is dependent on NAMPT expression
por: Zhuang, Yongxian, et al.
Publicado: (2023)

Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC
por: Cao, Hongxin, et al.
Publicado: (2016)

The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC
por: Jin, Dan, et al.
Publicado: (2018)

Supporting MRT mental health: Through COVID-19 and beyond
por: Corrente, Melissa, et al.
Publicado: (2023)

Top quark physics with ATLAS &amp;amp;amp;amp; CMS
por: Onofre, A
Publicado: (2009)

Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status
por: Stephenne, X., et al.
Publicado: (2011)

A possible role for AMP-activated protein kinase activated by metformin and AICAR in human granulosa cells
por: Kai, Yufuko, et al.
Publicado: (2015)

Recent Advances in Immunotherapy in Metastatic NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

C++ AMP: accelerated massive parallelism with Microsoft Visual C++
por: Gregory, Kate, et al.
Publicado: (2012)

Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction
por: Chen, Hengyi, et al.
Publicado: (2017)

Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis
por: Jin, Dan, et al.
Publicado: (2020)

Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways
por: Zhu, Zhongling, et al.
Publicado: (2021)

Upregulation of endogenous TRAIL-elicited apoptosis is essential for metformin-mediated antitumor activity against TNBC and NSCLC
por: Liu, Shuang, et al.
Publicado: (2021)

A World of Gorse: Persistence of Ulex europaeus in Managed Landscapes
por: Broadfield, Nicholas, et al.
Publicado: (2019)

EF24 exerts cytotoxicity against NSCLC via inducing ROS accumulation
por: Chang, Minghui, et al.
Publicado: (2021)

The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy
por: Ali, Amr, et al.
Publicado: (2023)

Renoprotective Effects of Metformin are Independent of Organic Cation Transporters 1 & 2 and AMP-activated Protein Kinase in the Kidney
por: Christensen, Michael, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3qno65eh0qtk2142q37aqsb5m8